Whether OC cells can also activate the miR-630/KLF6/NF-kB pathway in tumor cells in an autocrine matter, and whether the miR-630 carried by EVs can be used as an entry point for OC therapy needs further investigation. This evidence concerns the gene KLF6 and neoplasm.